Cargando…
Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis
PURPOSE: The purpose of this study was to assess the efficacy and toxicities of adding molecular targeted agents (MTAs) to first-line chemotherapy in the treatment of advanced biliary tract cancer (BTC). METHODS: An extensive search for relevant clinical trials was conducted in electronic databases...
Autores principales: | Zhao, Sheng, Miao, Yanping, Wang, Ruijun, Guo, Haidong, Jin, Feng, Guo, Xiuling, Luo, Tianyou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094605/ https://www.ncbi.nlm.nih.gov/pubmed/27822072 http://dx.doi.org/10.2147/OTT.S110926 |
Ejemplares similares
-
Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
por: Zhao, Qiuling, et al.
Publicado: (2023) -
The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis
por: Zheng, Wei, et al.
Publicado: (2019) -
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Ye, Zhuo-miao, et al.
Publicado: (2023) -
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
por: Fiteni, Frédéric, et al.
Publicado: (2014) -
A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma
por: Zeng, Jie, et al.
Publicado: (2023)